Pre-clinical validation complete
Numerical simulations and lab-based pre-clinical tests confirm detection of tumours as small as 3 mm in radius, even deep in tissue. Peer-reviewed publication in progress.
POSICS provides direct visual information at the moment when critical decisions are made: during surgery itself. This page explains the system, the surgical workflow, and the validation milestones.
POSICS does not replace pre-operative imaging. It brings that information visually into the operating room, where it matters most.
Standard MRI, CT or PET imaging identifies tumour location. No change to existing protocols.
A tumour-specific radio-pharmaceutical tracer is administered before the operation, a standard practice in radio-guided surgery.
The camera is placed externally on the body. The surgeon wears AR glasses and sees a live overlay of tumoral tissue, showing exactly where to cut and when to stop.
After excision, the camera can be used to verify the surgical site. A real-time completeness check, before wound closure.
It listens for the tracer's signal from outside the body and reconstructs, in real time, a visual map of the tumour. Nothing touches the surgical field.
The image is laid directly over the patient, in the surgeon's own line of sight. No screen to glance at. No looking away.
Fine enough to read a tumour's shape, its margins, the tissue around it. Lesions as small as 3 mm appear, even deep in tissue.
Near real-time. The surgeon moves the camera and the image follows, without breaking the rhythm of the operation.
Sub-millimetre resolution over a 3 × 3 cm active area, with only four readout channels — sixteen times fewer than a standard array. Compact. Light. Scalable.
The same instrument serves the pre-operative outpatient and the operating room — one tool, many moments in the patient's path.
POSICS doesn't change how surgeons operate.
It changes what they can see while they do.
POSICS is not a concept. It is a working prototype backed by peer-reviewed results, competitive grants, and institutional partnerships.
Numerical simulations and lab-based pre-clinical tests confirm detection of tumours as small as 3 mm in radius, even deep in tissue. Peer-reviewed publication in progress.
Over CHF 600,000 in competitive grants (ATTRACT Phase 1 & 2, HEPIA). Recognition from FONGIT and Swiss Startups. HUG Prize recipient.
Physics, detector engineering, medical imaging, AR software development, and clinical surgery. All the disciplines needed to bring POSICS from prototype to clinical use are represented.
The prototype is ready. Clinical validation on human tissue is the final step before full TRL 6 readiness and hospital deployment.